H.C. Wainwright analyst Robert Burns raised the firm’s price target on Replimune (REPL) to $21 from $17 and keeps a Buy rating on the shares. The firm expects a “relatively uneventful” FDA review ...

Shares of Exicure Inc. surged more than 25% on Thursday, reaching levels last seen over three weeks ago, following the ...

Recent results raise hope of new "broad, pan-tumor platform" like Keytruda. The emerging drugs are bispecific antibodies that ...

Replimune Group, Inc. REPL announced that the FDA has accepted the biologics license application (BLA) for its lead pipeline ...

2025 is set to be a game-changing year for cancer research, with cutting-edge therapies and technologies driving unprecedented progress in oncology.

Ovarian Cancer Market Analysis & Forecast by Diagnosis 2023 - 2034 (Revenue USD Bn) U.S. About is the world's leading source for international market research reports and market data. We provide you ...

During a Case-Based Roundtable® event, Kathryn E. Beckermann, MD, PhD, discussed second-line regimens with event participants ...

Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation ("GPCR"), pursuant to ...

Pharmac is also consulting on a joint proposal with Medsafe to increase access to ADHD medicines. The consultation is ...

The pharma expects a modest financial headwind this year from changes to Medicare prescription drug benefits under the Inflation Reduction Act.

Research analysts at William Blair upped their Q4 2024 earnings estimates for Bristol-Myers Squibb in a report released on Tuesday, January 21st. William Blair analyst M. Phipps now forecasts that the ...

An exhibit at the Chicago Cultural Center is coming under fire. It includes a large puppet titled, "US-Israel War Machine." A brush fire erupted amid powerful winds Wednesday afternoon in the ...